← Back to patent-cliff list
Flurpiridaz F-18
Tier C — Watch / tradeFlurpiridaz F-18
Bristol Myers Squibb
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：Mitochondrial complex I (NADH dehydrogenase)
Brand：FLYRCADO
Indications (approved)：Coronary artery disease, Ischaemic heart disease, Diagnostic agent
Regional status
US
Approved
2024-09-27
EU
Phase III
2011-06-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Flurpiridaz F-18?
Approved indications include: Coronary artery disease, Ischaemic heart disease, Diagnostic agent.
When does the Flurpiridaz F-18 patent expire?
No public expiry year is available for Flurpiridaz F-18 yet; this page updates once verified.
How do I get a quote for Flurpiridaz F-18 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27